Therapeutic Decision-Making for Urinary Tract Infections in Dogs

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Differentiating uncomplicated from complicated canine urinary tract infections (UTIs) is paramount, dictating the necessity for urine culture, imaging, and treatment duration. Uncomplicated UTIs in healthy dogs may be treated empirically with first-line agents like amoxicillin or trimethoprim-sulfonamide, while complicated infections require culture and susceptibility testing prior to therapy.
• Urine culture and susceptibility testing are critical decision points, particularly for recurrent, complicated, or suspected resistant infections, and should precede selection of second-line agents. Quantitative interpretation of urine culture results is essential, with cystocentesis yielding >1,000 CFU/mL and free-catch samples >100,000 CFU/mL indicating true infection.
• Antimicrobial stewardship mandates reserving critically important antimicrobials, such as fluoroquinolones, for confirmed resistant infections, avoiding their use as first-line empiric agents. Treatment duration varies, with 7 days typically sufficient for uncomplicated cystitis, while complicated infections or pyelonephritis necessitate 14 or more days of therapy.
• Pathogen biology, particularly the virulence factors of Escherichia coli (e.g., adhesins, hemolysin) and the intrinsic resistance of Enterococcus species to certain antibiotic classes, influences therapeutic choices. E. coli accounts for the majority of canine UTIs, while Enterococcus infections often require specific Gram-positive coverage and are frequently hospital-associated or follow prior antimicrobial exposure.
• Monitoring for treatment efficacy includes assessing clinical signs within 48-72 hours and performing a recheck urine culture 5-7 days after therapy completion to confirm bacteriologic cure. Persistent pyuria or bacteriuria on recheck urinalysis necessitates further investigation, potentially including repeat culture and susceptibility testing to distinguish relapse from reinfection.
• Imaging modalities such as radiography and ultrasonography are indicated for recurrent infections, treatment failures, or suspected structural abnormalities like uroliths, which can perpetuate infection and require specific management beyond antibiotics.

This article provides a structured framework for selecting and monitoring antibiotic therapy for urinary tract infections (UTIs) in dogs. It is written for veterinary students who understand clinical terminology and basic infectious disease principles but need a reproducible decision pathway for common and complicated presentations. The content addresses diagnostic reasoning, drug class selection, duration of therapy, and follow-up strategies, with explicit attention to antimicrobial stewardship and the growing problem of resistant uropathogens. Specific milligram per kilogram doses are intentionally excluded, current formulary and label references must be consulted before prescribing.

The clinical question this article answers is direct: once a canine UTI is confirmed or strongly suspected, how does the clinician choose an antibiotic, decide how long to treat, and determine what monitoring proves cure? The answer depends on distinguishing uncomplicated from complicated infections, recognizing host and pathogen factors that predict failure, and applying culture and susceptibility testing at the correct decision points. The framework presented here integrates published evidence on uropathogen biology with practical stewardship principles.

At a Glance

Pathogen Biology and Virulence

Uropathogenic Escherichia coli accounts for the majority of canine UTIs, and its ability to cause disease depends on specific bacterial traits instead of random opportunism. As described in the classic review of virulence factors in E. coli urinary tract infection, adhesins such as P fimbriae and type 1 fimbriae allow attachment to uroepithelial surfaces, while hemolysin, aerobactin, and K capsule contribute to tissue invasion and immune evasion. Strains expressing multiple virulence factors tend to produce more severe infections, and different factor combinations favour cystitis, pyelonephritis, or asymptomatic bacteriuria. This distinction matters clinically because a low-virulence isolate in a voided sample may represent contamination or colonisation instead of true infection.

The population structure of uropathogenic E. coli has clinical implications for resistance surveillance. A substantial body of evidence reviewed in the context of food-borne origins of extraintestinal E. coli infections indicates that many human urinary isolates belong to a limited number of extraintestinal pathogenic lineages, and some of the most resistant strains appear to have food animal reservoirs. Veterinary clinicians should assume that canine uropathogens exist within the same broader ecological network, which means local resistance patterns can shift with agricultural antimicrobial use and are not static within a practice region.

Enterococci are the second most common Gram-positive uropathogens in dogs and present a different therapeutic problem. The ecology, epidemiology and virulence of Enterococcus demonstrate remarkable environmental hardiness and intrinsic resistance to many commonly used antibiotics, including cephalosporins and trimethoprim-sulfonamides. Enterococcal UTIs are frequently hospital-associated or follow prior antimicrobial exposure, and their treatment requires drugs with specific Gram-positive activity. Clinicians should not assume that a broad-spectrum agent chosen for Gram-negative coverage will clear an enterococcal infection.

Host Factors and Infection Classification

The distinction between uncomplicated and complicated UTI drives nearly every subsequent decision. An uncomplicated infection occurs in an otherwise healthy dog with normal urinary tract anatomy and function, typically a female with acute onset of clinical signs. A complicated infection exists when structural abnormalities, urolithiasis, chronic kidney disease, endocrinopathy such as diabetes mellitus or hyperadrenocorticism, immunosuppressive therapy, or urinary catheterization are present. Male dogs are generally considered complicated because the longer urethra and prostate gland create additional barriers to bacterial clearance.

Host defense mechanisms in the urinary tract include urine flow, mucosal glycosaminoglycan layers, secretory IgA, and innate immune responses. Disruption of any of these, whether by anatomic abnormality or systemic disease, lowers the bacterial inoculum required to establish infection and increases the likelihood of tissue invasion. The MSD Veterinary Manual professional edition provides a comprehensive overview of these host defense mechanisms and their clinical correlates, and it remains a useful reference for reviewing the pathophysiology of ascending infection.

Recurrent UTI, defined as two or more infections within six months or three within one year, warrants a different diagnostic approach than a first episode. Each recurrence should prompt consideration of whether the same strain persists despite therapy, a new strain has been introduced, or an underlying predisposing factor has been overlooked. Imaging and contrast studies are indicated in recurrent cases to identify structural lesions that will not resolve with antibiotics alone.

Antimicrobial Stewardship Principles

Antimicrobial stewardship in veterinary practice requires selecting the narrowest effective drug, at the correct dose, for the shortest duration that achieves cure. The AVMA practice resources emphasize that judicious use of antimicrobials preserves drug efficacy for both animal and human patients, particularly for classes shared across species. Fluoroquinolones and third-generation cephalosporins are critically important antimicrobials in human medicine, and their veterinary use should be reserved for infections where susceptibility testing confirms no equally effective alternative.

Empiric therapy is justified only when clinical signs are acute, the patient is systemically stable, and no risk factors for resistant infection are present. In these cases, a first-line agent with activity against common uropathogens is appropriate while awaiting culture results, or without culture if the clinician judges the probability of resistance to be low. When risk factors exist, including prior antimicrobial exposure within the previous three months, recurrent infection, or recent hospitalization, culture and susceptibility testing should precede therapy whenever the patient's condition permits.

The emergence of multidrug-resistant Gram-negative organizms has outpaced the development of new veterinary antimicrobials. Novel agents such as ceftolozane-tazobactam, reviewed for their activity against multidrug-resistant Gram-negative bacilli, offer options in human medicine but are rarely available or affordable in veterinary practice. This gap reinforces the need to protect existing veterinary drugs through disciplined prescribing and to pursue non-antimicrobial management strategies where they exist.

Diagnostic Confirmation and Specimen Quality

The decision to treat a urinary tract infection begins with confirming that true bacteriuria exists instead of contamination or asymptomatic colonisation. A urinalysis showing pyuria, hematuria, or bacteriuria supports the diagnosis, but quantitative culture remains the reference standard. Cystocentesis is the preferred collection method because it avoids distal urethral and vaginal contamination. Free-catch midstream samples are acceptable when cystocentesis is not feasible, but quantitative thresholds must be adjusted. A cystocentesis sample yielding more than 1,000 colony-forming units per milliliter indicates true infection, whereas free-catch samples require more than 100,000 CFU/mL for the same interpretation. Catheterized samples fall between these thresholds.

Urine culture and susceptibility testing should be performed before first antimicrobial selection in any patient with recurrent infection, suspected pyelonephritis, or recent antimicrobial exposure. For a first uncomplicated cystitis episode in an otherwise healthy dog, empirical therapy is reasonable, but culture is still advisable when the clinician practises in a region with high rates of resistance. The MSD Veterinary Manual provides species-specific guidance on specimen handling and interpretation that supports these decisions.

Empirical Therapy Selection

When empirical therapy is chosen, the drug should target the organizms most likely to be present. Escherichia coli accounts for the majority of canine UTIs, with staphylococci, enterococci, Proteus, and Klebsiella species comprising most of the remainder. The uropathogenic properties of E. coli, including adhesins and other virulence factors, are well characterized and explain its dominance in this infection site Johnson, Virulence factors in Escherichia coli urinary tract infection. Empirical choices should therefore cover Gram-negative enteric organizms and Gram-positive cocci.

Amoxicillin remains a reasonable first choice for uncomplicated cystitis in a dog with no recent antimicrobial history, because it achieves high urine concentrations and covers common susceptible isolates. However, resistance among E. coli to aminopenicillins is common, and the clinician should verify susceptibility whenever the response to therapy is incomplete. Potentiated amoxicillin or a first-generation cephalosporin offers broader Gram-negative coverage. Fluoroquinolones should be reserved for cases where resistance patterns or patient factors demand them, consistent with antimicrobial stewardship principles. The AVMA practice resources outline stewardship expectations that apply to companion animal practice.

The duration of therapy for uncomplicated cystitis is typically 7 to 14 days, with shorter courses considered for uncomplicated cases. Pyelonephritis requires longer therapy, usually 3 to 4 weeks, and benefits from a drug that achieves therapeutic concentrations in renal parenchyma instead of urine alone. The distinction between lower and upper tract infection therefore changes both drug selection and treatment length.

Culture-Guided Therapy and Resistance Interpretation

When culture results return, the clinician must interpret the susceptibility panel in the context of the drug's pharmacokinetics in the urinary tract. A drug reported as intermediate by broth dilution standards may still be effective for cystitis because urine concentrations of many antimicrobials exceed serum concentrations by a wide margin. Conversely, an isolate reported as susceptible to a drug that is extensively protein bound or poorly excreted in urine may fail clinically. The laboratory report is a starting point, not the final word.

Enterococci deserve particular attention. These organizms are intrinsically resistant to cephalosporins and many other commonly used drugs, and they express a range of virulence factors that aid colonisation Fisher and Phillips, The ecology, epidemiology and virulence of Enterococcus. Amoxicillin is often effective for enterococcal cystitis because of the high urine concentrations achieved, even when serum-based interpretive criteria suggest intermediate susceptibility. Nitrofurantoin is another option for lower tract enterococcal infection. The clinician should not reflexively treat enterococcal bacteriuria in a dog that is asymptomatic, because enterococci can colonise the urinary tract without causing disease.

Multidrug-resistant Gram-negative infections require a structured approach. Extended-spectrum beta-lactamase producing E. coli and Klebsiella are increasingly encountered in companion animals. Carbapenems are the classic last-resort drugs for these organizms, but their use in veterinary practice raises stewardship concerns. The emergence of carbapenem-resistant Enterobacteriaceae with enhanced virulence and persistence in the urinary tract has been documented in human medicine Ernst et al., Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae, and the same resistance mechanisms can appear in canine isolates. When such organizms are identified, consultation with a veterinary microbiologist or infectious disease specialist is warranted before selecting therapy.

Monitoring and Treatment Response

Clinical improvement should be evident within 48 to 72 hours of starting appropriate therapy. Lack of response by that point demands re-evaluation instead of simply extending the same drug. A repeat urine culture should be collected before any change in therapy, because the original isolate may have developed resistance or a different organizm may have emerged.

A test of cure culture performed 7 to 14 days after the end of therapy is the standard for confirming bacteriologic resolution. This is particularly important in dogs with recurrent infection, because clinical resolution can occur despite persistent bacteriuria. The distinction between relapse and reinfection relies on comparing the susceptibility profile of the original and subsequent isolates. Relapse with the same organizm suggests inadequate therapy, a sequestered focus such as a urolith or renal abscess, or an anatomical abnormality. Reinfection with a different organizm points to an ongoing predisposing factor that requires investigation.

Imaging and Comorbidity Assessment

Imaging is indicated when infection is recurrent, fails to respond to appropriate therapy, or is associated with systemic signs. Survey radiography detects radiopaque uroliths and provides an assessment of bladder size and position. Ultrasonography identifies bladder wall thickening, intraluminal masses, uroliths that are not radiopaque, and renal or ureteral abnormalities. Contrast studies or computed tomography may be needed to characterize ectopic ureters, urethral strictures, or diverticula. The Davis-Thompson Foundation pathology resources include case material that illustrates the gross and histologic findings associated with chronic urinary tract infection, which can help the clinician anticipate the lesions that imaging may reveal.

Urolithiasis is a common comorbidity that perpetuates infection. Struvite stones are frequently infection induced, and their dissolution requires both antimicrobial therapy and dietary management. Calcium oxalate stones are not infection induced but can become secondarily infected. Surgical or minimally invasive removal is often required for stones that do not dissolve. The presence of a urolith changes the expected response to therapy and mandates imaging follow-up to confirm stone resolution.

Documentation and Stewardship Records

The medical record should document the indication for antimicrobial therapy, the drug selected, the dose and duration, the culture results, and the planned monitoring schedule. This documentation supports antimicrobial stewardship audits and provides a basis for evaluating treatment outcomes. The WOAH terrestrial animal health standards address responsible antimicrobial use in animals and provide a framework that companion animal practitioners can adapt to their setting. Recording the rationale for choosing a particular drug, especially when a broader-spectrum agent is selected, demonstrates that the decision was deliberate and evidence informed.

When a dog fails therapy despite appropriate drug selection and duration, the clinician should investigate host factors instead of simply rotating antimicrobials. Immunosuppressive disease, endocrinopathy such as diabetes mellitus or hyperadrenocorticism, urolithiasis, and anatomical abnormalities all predispose to persistent infection. Addressing these underlying conditions is often more important than finding a different antibiotic. The evidence base for specific management strategies in these complex cases is limited, and referral to an internal medicine specialist should be considered when the clinician is uncertain.

Recognized Complications and Failure Modes

The most common therapeutic failure is persistence of infection despite an apparently appropriate antibiotic. This occurs when the selected drug does not reach effective urinary concentrations, when the organizm is resistant despite in vitro susceptibility, or when a structural or functional abnormality prevents clearance. Early detection depends on the mandatory recheck urine culture 5 to 7 days after completing therapy, not on clinical improvement alone. Clinical resolution can occur with bacterial persistence, and bacteriuria can persist without clinical signs.

Recurrent infection is classified as relapse or reinfection. Relapse, recurrence with the same organizm within weeks of stopping therapy, suggests inadequate tissue penetration, a protected nidus such as uroliths or pyelonephritis, or antimicrobial resistance that emerged during treatment. Reinfection, recurrence with a different organizm after a longer interval, points to an ongoing host predisposition such as poor sphincter function, vulvar fold dermatitis, or incomplete voiding. The distinction requires culture of each episode with susceptibility testing, because empirical retreatment of a relapse with the same drug class will fail again.

Ascending infection with renal involvement is a recognized progression of lower urinary tract infection. Uropathogenic strains of Escherichia coli express virulence factors that favour pyelonephritis, including P fimbriae and hemolysin, and the severity of infection generally increases with the number of virulence factors expressed Virulence factors in Escherichia coli urinary tract infection. Detect pyelonephritis early by persistent fever, renal pain on palpation, or leukocytosis, and confirm with urine sediment findings and imaging. Delayed recognition converts a treatable cystitis into a source of bacteremia.

Antimicrobial resistance emerging during therapy is a distinct failure mode. Enterococci are intrinsically resistant to many commonly used agents and can acquire glycopeptide resistance, which complicates treatment of nosocomial urinary infections The ecology, epidemiology and virulence of Enterococcus. Resistance can also be selected in Gram-negative organizms during a course of therapy, particularly when drug concentrations at the infection site are marginal. The discriminating check is a repeat culture performed before changing therapy, not substitution based on clinical impression.

Common Errors and Corrective Actions

The most frequent error is treating a positive culture without assessing specimen quality. A culture grown from a free-catch sample contaminated by periurethral flora does not confirm infection, and treating it selects resistance without benefit. Corrective action is to interpret quantitative counts against the collection method and to repeat sampling by cystocentesis when the result is ambiguous.

A second error is choosing an antibiotic that achieves poor urinary concentrations for the identified pathogen. Nitrofurantoin, for example, is useful for cystitis but does not treat tissue infection. Fosfomycin has unusual resistance profiles that standard disk diffusion may not predict reliably. The corrective action is to verify that the drug's pharmacokinetic profile matches the infection site and to consult a current formulary for susceptibility breakpoints relevant to urinary concentrations.

A third error is stopping therapy at the point of clinical improvement. Clinical signs resolve before bacterial eradication in many patients, and premature discontinuation selects for resistant subpopulations. The corrective action is to complete the prescribed course and to perform the scheduled recheck culture regardless of clinical status.

A fourth error is repeating the same antibiotic after an apparent recurrence without culture. This wastes a drug, risks toxicity, and delays identification of a resistant organizm. The corrective action is to culture every recurrence and to compare the isolate with the previous one to distinguish relapse from reinfection.

Limitations of the Evidence and Areas of Disagreement

The evidence base for canine UTI therapy is thinner than for human medicine. Most recommendations derive from human studies, extrapolation from pharmacokinetic data, and expert opinion instead of randomised controlled trials in dogs. Duration of therapy is a particular area of disagreement. Some authorities advocate short courses of 3 to 5 days for uncomplicated cystitis, while others recommend 10 to 14 days, and the optimal duration for complicated infections is not established.

The clinical significance of asymptomatic bacteriuria in dogs remains contested. In humans, treatment of asymptomatic bacteriuria is discouraged except in specific populations, and some veterinary experts argue for a similar approach. Others maintain that any bacteriuria in dogs warrants treatment because of the difficulty excluding subclinical pyelonephritis. The MSD Veterinary Manual provides species-specific guidance on this question, but the underlying evidence is limited MSD Veterinary Manual, Professional Edition.

Interpretation of susceptibility testing also carries uncertainty. Breakpoints are often derived from human serum concentrations instead of canine urinary concentrations, and a report of resistance may not predict failure for a drug concentrated in urine. Conversely, in vitro susceptibility does not guarantee clinical success when host defenses are impaired. The AVMA practice resources address antimicrobial stewardship principles that apply to these interpretive decisions American Veterinary Medical Association practice resources.

Escalation and Referral Criteria

Referral or specialist consultation is warranted when infection persists after two appropriately selected courses of therapy, when imaging identifies uroliths, neoplasia, or anatomical anomalies, or when renal function is deteriorating. A veterinary internal medicine specialist should evaluate recurrent pyelonephritis, suspected ureteral or urethral obstruction, and infections caused by organizms with resistance patterns that limit oral options.

Laboratory involvement extends beyond routine culture. Reference laboratories can perform extended susceptibility testing, including minimum inhibitory concentration determination for drugs not on the routine panel, and can identify emerging resistance mechanisms. For multidrug-resistant organizms, consultation with a veterinary microbiologist or clinical pharmacologist is appropriate before selecting a drug with a narrow therapeutic index.

Regulatory reporting obligations vary by jurisdiction. Some multidrug-resistant organizms, particularly those with zoonotic potential, may be notifiable. The World Organization for Animal Health terrestrial animal health standards address surveillance and reporting expectations for antimicrobial resistance in animal populations WOAH terrestrial animal health code. Veterinarians should confirm local requirements, as reporting rules differ between countries and regions.

Troubleshooting Table

Frequently Asked Questions

How Should I Manage a Suspected UTI When Culture Is Not Affordable for the Owner?

When culture is declined, document the financial limitation and proceed with a structured empirical approach. Select a first-line agent based on the patient's infection classification, prior antibiotic history, and local resistance patterns. Schedule a recheck examination and urine analysis 5 to 7 days after completing therapy. If clinical signs persist or bacteriuria recurs, explain that culture is now the most cost-effective step because repeated empirical courses risk selecting resistant organizms. The MSD Veterinary Manual provides species-specific guidance on empirical drug selection and monitoring protocols. A positive clinical response does not confirm bacteriologic cure, so repeat urinalysis remains mandatory.

What Should I Do When the Laboratory Reports an Enterococcus Species on Culture?

Enterococci are common contaminants and low-grade pathogens, so first determine whether the isolate represents true infection or specimen contamination. Review the urine collection method, quantitative colony count, and presence of pyuria. Enterococci possess colonization factors that facilitate urinary tract adherence, but their clinical significance depends on host immune status and concurrent disease. If the patient is asymptomatic, repeat sampling before treating. If infection is confirmed, recognize that enterococci are intrinsically resistant to many first-line drugs, and choose an agent with documented activity based on susceptibility testing. The ecology and virulence of Enterococcus support treating these isolates as opportunists instead of primary pathogens.

How Do I Adjust My Approach for a Dog With Recurrent UTI and No Identifiable Comorbidity?

Recurrent infection without an obvious structural or metabolic cause warrants a systematic reassessment instead of repeated short courses of antibiotics. Review the original culture results to confirm the same strain is recurring instead of a new infection. Evaluate the urine collection method, because perineal contamination produces misleading cultures. Consider imaging to exclude uroliths, polyps, or neoplasia that may have been missed initially. Discuss with the owner the possibility of dietary or environmental factors that promote bacterial persistence. The virulence factors of uropathogenic E. coli explain why certain strains establish persistent infection more readily than others, which supports a lower threshold for advanced diagnostics in recurrent cases.

What Records Should I Keep for Antibiotic Prescribing in UTI Cases?

Maintain a written record for every antibiotic prescription that includes the suspected or confirmed diagnosis, drug name, dose, duration, and the basis for drug selection. Note whether therapy was empirical or culture-guided, and record the culture results when available. Document owner discussions about stewardship, including any refusal of recommended diagnostics. These records support future prescribing decisions for the same patient and allow you to track resistance patterns in your practice population. The AVMA practice resources offer guidance on professional documentation standards. Consistent record keeping also protects you if a treatment failure is later questioned.

How Should I Explain a Resistant Infection to a Frustrated Owner?

Use concrete language that separates the infection from the dog's behavior or the owner's care. Explain that bacteria can survive multiple drugs and that this is an expected outcome of antibiotic use, not a failure of treatment. Describe the next step as a targeted approach: the culture tells us which drug will work, and the susceptibility test tells us the dose needed. Emphasize that giving more antibiotics without this information risks further resistance. Acknowledge the cost and time involved, and offer a clear timeline for recheck. The food-borne origins of resistant E. coli can help owners understand that resistant strains circulate in the environment and are not unique to their pet.

When Should I Refer a UTI Case to a Specialist?

Refer when infection persists despite two appropriately selected antibiotic courses, when imaging reveals a lesion requiring surgical intervention, or when the patient has concurrent disease that complicates therapy. Refer also when you lack access to cystoscopy or advanced imaging needed to identify a nidus of infection. Specialists can perform urethrocystoscopy, obtain biopsy samples, and manage nephrolithiasis or ectopic ureters. The Davis-Thompson Foundation pathology resources provide case material that illustrates the range of lesions underlying refractory urinary tract infections. Before referral, send the complete record including all culture results, imaging reports, and a chronology of treatments so the specialist does not repeat failed diagnostics.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Virulence factors in Escherichia coli urinary tract infection.. 1991.
• Food-borne origins of Escherichia coli causing extraintestinal infections.. 2012.
• The ecology, epidemiology and virulence of Enterococcus.. 2009.
• Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria.. 2015.
• Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae.. 2020.
• Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.. 2014.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Therapeutic Decision-Making for Bacterial Skin Infections in Dogs
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Therapeutic Decision-Making for Autoimmune Disease in Dogs
• Therapeutic Decision-Making for Gastrointestinal Ulcers in Veterinary Patients
• Therapeutic Monitoring of Antiepileptic Drugs in Dogs and Cats

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.